How old is patient?
What is Chlorphenamine (Vegaskine)?
Chlorphenamine (Vegaskine) is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
Chlorphenamine (Vegaskine) is used to treat runny nose, sneezing, itching, and watery eyes caused by allergies, the common cold, or the flu.
Chlorphenamine (Vegaskine) may also be used for purposes not listed in this medication guide.
Chlorphenamine (Vegaskine) indications
Infectious-inflammatory diseases caused by microorganisms susceptible to ciprofloxacin, including respiratory diseases, diseases of abdominal and pelvic organs, bones, joints, skin, septicemia; severe infections of ENT organs. Treatment of postoperative infections. Prevention and treatment of infections in patients with reduced immunity.
For Chlorphenamine (Vegaskine) Citadel Fine Pharmaceuticals local use: acute and subacute conjunctivitis, blepharoconjunctivitis, blepharitis, bacterial corneal ulcers, keratitis, keratoconjunctivitis, chronic dacryocystitis, meybomity. Infectious lesions in the eyes from injury or contact with foreign bodies. Preoperative prophylaxis in ophthalmic surgery.
How should I use Chlorphenamine (Vegaskine)?
Use Chlorphenamine (Vegaskine) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Chlorphenamine (Vegaskine) may be taken with or without food.
- If you miss a dose of Chlorphenamine (Vegaskine), take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Chlorphenamine (Vegaskine).
Uses of Chlorphenamine (Vegaskine) in details
Chlorphenamine (Vegaskine) is used to relieve symptoms of runny nose, sneezing, itching, and watery eyes caused by allergies, the common cold, or the flu and allergies due to food and insect bites and hay fever.
Chlorphenamine (Vegaskine) description
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. [PubChem]
Chlorphenamine (Vegaskine) dosage
Individual. For oral administration dose of Chlorphenamine (Vegaskine) Citadel Fine Pharmaceuticals is 250-750 mg 2 times / day. Treatment duration is from 7-10 days to 4 weeks.
For IV administration a single dose is 200-400 mg, the multiplicity of the introduction is 2 times / day, duration of treatment - 1-2 weeks and more if necessary. May be IV injected as jet but more preferably a drip for 30 minutes.
When Chlorphenamine (Vegaskine) Citadel Fine Pharmaceuticals applied topically instilled 1-2 drops into the lower conjunctival sac of the affected eye every 1-4 hours. After improving the intervals between instillation can be increased. The maximum oral daily dose for adults is 1.5 g.
Chlorphenamine (Vegaskine) interactions
Activity increases when combined with beta-lactam antibiotics, aminoglycosides, vancomycin, clindamycin, metronidazole. Sukralfat, bismuth preparations, antacids containing aluminum ions, magnesium or calcium, cimetidine, ranitidine, vitamin and mineral supplement, iron sulfate, zinc, didanosine (recommended for 2 hours before or 4 hours after these drugs) reduce the suction. Probenecid, azlocillin increase the concentration in the blood. Decreases clearance and increases in plasma caffeine, aminophylline and theophylline (increased likelihood of side effects). Chlorphenamine (Vegaskine) Citadel Fine Pharmaceuticals enhances the effect of warfarin and other oral anticoagulants (prolongs bleeding time). Increases nephrotoxicity of cyclosporine, increase the risk of CNS excitability and convulsive reactions against the background of NSAIDs. Medicines alkalinizing the urine (citrates, sodium bicarbonate, carbonic anhydrase inhibitors) reduce the solubility (increases the probability of crystalluria). Infusion solutions of ciprofloxacin ready to use can be combined with infusion solutions: 0.9% sodium chloride solution, Ringer's solution, Ringer lactate, 5 and 10% dextrose, 10% solution of fructose, and a solution containing 5% dextrose with 0,225 or 0.45% sodium chloride. Incompatible with solutions having a pH > 7.
Chlorphenamine (Vegaskine) side effects
Applies to Chlorphenamine (Vegaskine): capsules, controlled-release capsules, suspension drops, sustained-release capsules, syrup, tablets
Other dosage forms:
Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Seek medical attention right away if any of these SEVERE side effects occur while taking Chlorphenamine (Vegaskine) (the active ingredient contained in Chlorphenamine (Vegaskine) (Allergy))
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.
Chlorphenamine (Vegaskine) contraindications
Injection: Chlorphenamine (Vegaskine) is contraindicated in comatose states, in patients who have received large amounts of central-nervous-system depressants (alcohol, sedative hypnotics, including barbiturates, general anesthetics, narcotics, narcotic analgesics, tranquilizers, etc.), and in patients who have demonstrated an idiosyncrasy or hypersensitivity to promethazine.
Under no circumstances should promethazine be given by intra-arterial injection due to the likelihood of severe arteriospasm and the possibility of resultant gangrene
Chlorphenamine (Vegaskine) HCl injection should not be given by the subcutaneous route; evidence of chemical irritation has been noted, and necrotic lesions have resulted on rare occasions following subcutaneous injection. The preferred parenteral route of administration is by deep intramuscular injection.
Syrup, Tablets and Suppositories: Phenergan Tablets and Suppositories are contraindicated for use in pediatric patients less than two years of age.
Phenergan Tablets and Suppositories are contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines.
Antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms including asthma.
What is Paracetamol (Vegaskine)?
Paracetamol (Vegaskine) (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of Paracetamol (Vegaskine) of is not known.
Paracetamol (Vegaskine) is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint.
Paracetamol (Vegaskine) may also be used for other purposes not listed in this medication guide.
Paracetamol (Vegaskine) indications
For systemic use of Paracetamol (Vegaskine) Sante Naturelle: prevention and treatment of hypo- and avitaminosis of vitamin C; providing increased need for vitamin C during growth, pregnancy, lactation, with heavy loads, fatigue and during recovery after prolonged severe illness; in winter with an increased risk of infectious diseases.
For intravaginal use: chronic or recurrent vaginitis (bacterial vaginosis, nonspecific vaginitis) caused by the anaerobic flora (due to changes in pH of the vagina) in order to normalize disturbed vaginal microflora.
How should I use Paracetamol (Vegaskine)?
Use Paracetamol (Vegaskine) exactly as directed on the label, or as prescribed by your doctor.
Do not use more of this medication than is recommended. An overdose of Paracetamol (Vegaskine) can cause serious harm. The maximum amount for adults is 1 gram (1000 mg) per dose and 4 grams (4000 mg) per day. Using more Paracetamol (Vegaskine) could cause damage to your liver. If you drink more than three alcoholic beverages per day, talk to your doctor before taking Paracetamol (Vegaskine) and never use more than 2 grams (2000 mg) per day. If you are treating a child, use a pediatric form of Paracetamol (Vegaskine). Carefully follow the dosing directions on the medicine label. Do not give the medication to a child younger than 2 years old without the advice of a doctor.
Measure the liquid form of Paracetamol (Vegaskine) with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one. You may need to shake the liquid before each use. Follow the directions on the medicine label.
The Paracetamol (Vegaskine) chewable tablet must be chewed thoroughly before you swallow it.
Make sure your hands are dry when handling the Paracetamol (Vegaskine) disintegrating tablet. Place the tablet on your tongue. It will begin to dissolve right away. Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.
To use the Paracetamol (Vegaskine) effervescent granules, dissolve one packet of the granules in at least 4 ounces of water. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.
Do not take a Paracetamol (Vegaskine) rectal suppository by mouth. It is for use only in your rectum. Wash your hands before and after inserting the suppository.
Try to empty your bowel and bladder just before using the Paracetamol (Vegaskine) suppository. Remove the outer wrapper from the suppository before inserting it. Avoid handling the suppository too long or it will melt in your hands.
For best results from the suppository, lie down and insert the suppository pointed tip first into the rectum. Hold in the suppository for a few minutes. It will melt quickly once inserted and you should feel little or no discomfort while holding it in. Avoid using the bathroom just after inserting the suppository.
Stop using Paracetamol (Vegaskine) and call your doctor if:
you still have a fever after 3 days of use;
you still have pain after 7 days of use (or 5 days if treating a child);
you have a skin rash, ongoing headache, or any redness or swelling; or
if your symptoms get worse, or if you have any new symptoms.
Urine glucose tests may produce false results while you are taking Paracetamol (Vegaskine). Talk to your doctor if you are diabetic and you notice changes in your glucose levels during treatment.
Store Paracetamol (Vegaskine) at room temperature away from heat and moisture. The rectal suppositories can be stored at room temperature or in the refrigerator.
Uses of Paracetamol (Vegaskine) in details
This drug is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever.
How to use Paracetamol (Vegaskine)
Take this product by mouth as directed. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.
There are many brands and forms of acetaminophen available. Read the dosing instructions carefully for each product because the amount of acetaminophen may be different between products. Do not take more acetaminophen than recommended.
If you are giving acetaminophen to a child, be sure you use a product that is meant for children. Use your child's weight to find the right dose on the product package. If you don't know your child's weight, you can use their age.
For suspensions, shake the medication well before each dose. Some liquids do not need to be shaken before use. Follow all directions on the product package. Measure the liquid medication with the provided dose-measuring spoon/dropper/syringe to make sure you have the correct dose. Do not use a household spoon.
For rapidly-dissolving tablets, chew or allow to dissolve on the tongue, then swallow with or without water. For chewable tablets, chew thoroughly before swallowing.
Do not crush or chew extended-release tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.
For effervescent tablets, dissolve the dose in the recommended amount of water, then drink.
Pain medications work best if they are used as the first signs of pain occur. If you wait until the symptoms have worsened, the medication may not work as well.
Do not take this medication for fever for more than 3 days unless directed by your doctor. For adults, do not take this product for pain for more than 10 days (5 days in children) unless directed by your doctor. If the child has a sore throat (especially with high fever, headache, or nausea/vomiting), consult the doctor promptly.
Tell your doctor if your condition persists or worsens or if you develop new symptoms. If you think you may have a serious medical problem, get medical help right away.
Paracetamol (Vegaskine) description
Paracetamol (Vegaskine) is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms. Paracetamol (Vegaskine) exists as small alkaline deliquescent crystals with a saline tasteacinol was introduced to medicine as a solvent for uric acid. When taken into the body the drug is partly oxidized and partly eliminated unchanged. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successfulacinol was first introduced as an anthelmintic in 1953. A large number of piperazine compounds have anthelmintic Paracetamol (Vegaskine). Their mode of Paracetamol (Vegaskine) is generally by paralysing parasites, which allows the host body to easily remove or expel the invading organism.
Paracetamol (Vegaskine) dosage
General Dosing Information
Paracetamol (Vegaskine) may be given as a single or repeated dose for the treatment of acute pain or fever. No dose adjustment is required when converting between oral acetaminophen and Paracetamol (Vegaskine) dosing in adults and adolescents who weigh 50 kg and above. Calculated maximum daily dose of acetaminophen is based on all routes of administration (i.e., intravenous, oral, and rectal) and all products containing acetaminophen. Exceeding the maximum mg/kg daily dose of acetaminophen as described in Tables 1 and 2 may result in hepatic injury, including the risk of liver failure and death. To avoid the risk of overdose, ensure that the total amount of acetaminophen from all routes and from all credits does not exceed the maximum recommended dose.
Dosage: Adults and Adolescents
Adults and adolescents weighing 50 kg and over: the recommended dosage of Paracetamol (Vegaskine) is 1000 mg every 6 hours or 650 mg every 4 hours, with a maximum single dose of Paracetamol (Vegaskine) of 1000 mg, a minimum dosing interval of 4 hours, and a maximum daily dose of acetaminophen of 4000 mg per day (includes all routes of administration and all acetaminophen-containing products including combination products).
Adults and adolescents weighing under 50 kg: the recommended dosage of Paracetamol (Vegaskine) is 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours, with a maximum single dose of Paracetamol (Vegaskine) of 15 mg/kg, a minimum dosing interval of 4 hours, and a maximum daily dose of acetaminophen of 75 mg/kg per day (includes all routes of administration and all acetaminophen-containing products including combination products).
Table 1: Dosing for Adults and Adolescents
|Age group||Dose given every 4 hours||Dose given every 6 hours||Maximum single dose||Maximum total daily dose of acetaminophen (by all routes)|
|Adults and adolescents (13 years and older) weighing ≥ 50 kg||650 mg||1000 mg||1000 mg||4000 mg in 24 hours|
|Adults and adolescents (13 years and older) weighing < 50 kg||12.5 mg/kg||15 mg/kg||15 mg/kg (up to 750 mg)||75 mg/kg in 24 hours (up to 3750 mg)|
Children 2 to 12 years of age: the recommended dosage of Paracetamol (Vegaskine) is 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours, with a maximum single dose of Paracetamol (Vegaskine) of 15 mg/kg, a minimum dosing interval of 4 hours, and a maximum daily dose of acetaminophen of 75 mg/kg per day.
Table 2: Dosing for Children
|Age group||Dose given every 4 hours||Dose given every 6 hours||Maximum single dose||Maximum total daily dose of acetaminophen (by all routes)|
|Children 2 to 12 years of age||12.5 mg/kg||15 mg/kg||15 mg/kg (up to 750 mg)||75 mg/kg in 24 hours (up to 3750 mg)|
For adult and adolescent patients weighing ≥ 50 kg requiring 1000 mg doses of Paracetamol (Vegaskine), administer the dose by inserting a vented intravenous set through the septum of the 100 mL vial. Paracetamol (Vegaskine) may be administered without further dilution. Examine the vial contents before dose preparation or administering. DO NOT USE if particulate matter or discoloration is observed. Administer the contents of the vial intravenously over 15-minutes. Use aseptic technique when preparing Paracetamol (Vegaskine) for intravenous infusion. Do not add other medications to the Paracetamol (Vegaskine) vial or infusion device.
For doses less than 1000 mg, the appropriate dose must be withdrawn from the vial and placed into a separate container prior to administration. Using aseptic technique, withdraw the appropriate dose (650 mg or weight-based) from an intact sealed Paracetamol (Vegaskine) vial and place the measured dose in a separate empty, sterile container (e.g. glass bottle, plastic intravenous container, or syringe) for intravenous infusion to avoid the inadvertent delivery and administration of the total volume of the commercially available container. The entire 100 mL vial of Paracetamol (Vegaskine) is not intended for use in patients weighing less than 50 kg. Paracetamol (Vegaskine) is a single-use vial and the unused portion must be discarded.
Place small volume pediatric doses up to 60 mL in volume in a syringe and administer over 15 minutes using a syringe pump.
Monitor the end of the infusion in order to prevent the possibility of an air embolism, especially in cases where the Paracetamol (Vegaskine) infusion is the primary infusion.
Once the vacuum seal of the glass vial has been penetrated, or the contents transferred to another container, administer the dose of Paracetamol (Vegaskine) within 6 hours.
Do not add other medications to the Paracetamol (Vegaskine) solution. Diazepam and chlorpromazine hydrochloride are physically incompatible with Paracetamol (Vegaskine), therefore do not administer simultaneously.
Dosage Forms And Strengths
Paracetamol (Vegaskine) is a sterile, clear, colorless, non pyrogenic, preservative free, isotonic formulation of acetaminophen intended for intravenous infusion. Each 100 mL glass vial contains 1000 mg acetaminophen (10 mg/mL).
Storage And Handling
NDC 43825-102-01 - Paracetamol (Vegaskine)® (acetaminophen) Injection is supplied in a 100 mL glass vial containing 1000 mg acetaminophen (10 mg/mL) in cartons of 24 vials.
Paracetamol (Vegaskine) should be stored at 20°C to 25°C (68°F to 77°F).
For single use only. The product should be used within 6 hours after opening. Do not refrigerate or freeze.
Manufactured for: Mallinckrodt Hospital Products Inc., Hazelwood, MO 63042 USA. Revised: Dec 2014
Paracetamol (Vegaskine) interactions
With the simultaneous use with inducers of microsomal liver enzymes, means having hepatotoxic effect, increasing the risk of hepatotoxic Paracetamol (Vegaskine) of Paracetamol (Vegaskine).
With the simultaneous use of anticoagulants may be slight to moderate increase in prothrombin time.
With the simultaneous use of anticholinergics may decrease absorption of Paracetamol (Vegaskine).
With the simultaneous use of oral contraceptives accelerated excretion of Paracetamol (Vegaskine) from the body and may reduce its analgesic Paracetamol (Vegaskine).
With the simultaneous use with urological means reduced their effectiveness.
With the simultaneous use of activated charcoal reduced bioavailability of Paracetamol (Vegaskine).
When Paracetamol (Vegaskine) Guardian applied simultaneously with diazepam may decrease excretion of diazepam.
There have been reports about the possibility of enhancing mielodepression effect of zidovudine while applying with Paracetamol (Vegaskine). A case of severe toxic liver injury.
Described cases of toxic effects of Paracetamol (Vegaskine), while the use of isoniazid.
When applied simultaneously with carbamazepine, phenytoin, phenobarbital, primidonom decreases the effectiveness of Paracetamol (Vegaskine), which is caused by an increase in its metabolism and excretion from the body. Cases of hepatotoxicity, while the use of Paracetamol (Vegaskine) and phenobarbital.
In applying cholestyramine a period of less than 1 h after administration of Paracetamol (Vegaskine) may decrease of its absorption.
At simultaneous application with lamotrigine moderately increased excretion of lamotrigine from the body.
With the simultaneous use of metoclopramide may increase absorption of Paracetamol (Vegaskine) and its increased concentration in blood plasma.
When applied simultaneously with probenecid may decrease clearance of Paracetamol (Vegaskine), with rifampicin, sulfinpyrazone - may increase clearance of Paracetamol (Vegaskine) due to increasing its metabolism in the liver.
At simultaneous application of Paracetamol (Vegaskine) Guardian with ethinylestradiol increases absorption of Paracetamol (Vegaskine) from the gut.
Enhances the effect of indirect anticoagulants (coumarin derivatives and indandione). Antipyretic and analgesic activity of caffeine increases, reduce - rifampicin, phenobarbital and alcohol (accelerated biotransformation, inducing microsomal liver enzymes).
Paracetamol (Vegaskine) side effects
The following serious adverse reactions are discussed elsewhere in the labeling:
- Hepatic Injury
- Serious Skin Reactions
- Allergy and Hypersensitivity
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.
A total of 1020 adult patients have received Paracetamol (Vegaskine) in clinical trials, including 37.3% (n=380) who received 5 or more doses, and 17.0% (n=173) who received more than 10 doses. Most patients were treated with Paracetamol (Vegaskine) 1000 mg every 6 hours. A total of 13.1% (n=134) received Paracetamol (Vegaskine) 650 mg every 4 hours.
All adverse reactions that occurred in adult patients treated with either Paracetamol (Vegaskine) or placebo in repeated dose, placebo-controlled clinical trials at an incidence ≥ 3% and at a greater frequency than placebo are listed in Table 3. The most common adverse events in adult patients treated with Paracetamol (Vegaskine) (incidence ≥ 5% and greater than placebo) were nausea, vomiting, headache, and insomnia.
* Pyrexia adverse reaction frequency data is included in order to alert healthcare practitioners that the antipyretic effects of Paracetamol (Vegaskine) may mask fever.
|System Organ Class – Preferred Term|| Paracetamol (Vegaskine) |
| Placebo |
| Gastrointestinal Disorders |
| 138 (34) |
| 119 (31) |
| General Disorders and Administration Site Conditions |
|22 (5)||52 (14)|
| Nervous System Disorders |
|39 (10)||33 (9)|
| Psychiatric Disorders |
|30 (7)||21 (5)|
Other Adverse Reactions Observed During Clinical Studies of Paracetamol (Vegaskine) in Adults
The following additional treatment-emergent adverse reactions were reported by adult subjects treated with Paracetamol (Vegaskine) in all clinical trials (n=1020) that occurred with an incidence of at least 1% and at a frequency greater than placebo (n=525).
Blood and lymphatic system disorders: anemia
General disorders and administration site conditions: fatigue, infusion site pain, edema peripheral
Investigations: aspartate aminotransferase increased, breath sounds abnormal
Metabolism and nutrition disorders: hypokalemia
Musculoskeletal and connective tissue disorders: muscle spasms, trismus
Psychiatric disorders: anxiety
Respiratory, thoracic and mediastinal disorders: dyspnea
Vascular disorders: hypertension, hypotension
A total of 355 pediatric patients (47 neonates, 64 infants, 171 children, and 73 adolescents) have received Paracetamol (Vegaskine) in active-controlled (n=250) and open-label clinical trials (n=225), including 59.7% (n=212) who received 5 or more doses and 43.1% (n=153) who received more than 10 doses. Pediatric patients received Paracetamol (Vegaskine) doses up to 15 mg/kg on an every 4 hours, every 6 hours, or every 8 hours schedule. The maximum exposure was 7.7, 6.4, 6.8, and 7.1 days in neonates, infants, children, and adolescents, respectively.
The most common adverse events (incidence ≥ 5%) in pediatric patients treated with Paracetamol (Vegaskine) were nausea, vomiting, constipation, pruritus, agitation, and atelectasis.
Other Adverse Reactions Observed During Clinical Studies of Paracetamol (Vegaskine) in Pediatrics
The following additional treatment-emergent adverse reactions were reported by pediatric subjects treated with Paracetamol (Vegaskine) (n=355) that occurred with an incidence of at least 1%.
Blood and lymphatic system disorders: anemia
Cardiac disorders: tachycardia
Gastrointestinal disorders: abdominal pain, diarrhea
General disorders and administration site conditions: injection site pain, edema peripheral, pyrexia
Investigations: hepatic enzyme increase
Metabolism and nutrition disorders: hypoalbuminemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypervolemia
Musculoskeletal and connective tissue disorders: muscle spasm, pain in extremity
Nervous system disorders: headache
Psychiatric disorders: insomnia
Renal and urinary disorders: oliguria
Respiratory, thoracic and mediastinal disorders: pulmonary edema, hypoxia, pleural effusion, stridor, wheezing
Skin and subcutaneous tissue disorders: periorbital edema, rash
Vascular disorders: hypertension, hypotension
Paracetamol (Vegaskine) contraindications
Paracetamol (Vegaskine) should not be used in patients who have previously exhibited hypersensitivity to aspirin and/or nonsteroidal antiinflammatory agents. Paracetamol (Vegaskine) should not be given to patients with a recent history of gastrointestinal bleeding or in patients with bleeding disorders (e.g., hemophilia).
What is Phenobarbital (Vegaskine)?
Phenobarbital (Vegaskine) is in a group of drugs called barbiturates (bar-BIT-chur-ates). Phenobarbital (Vegaskine) slows the activity of your brain and nervous system.
Phenobarbital (Vegaskine) is used to treat or prevent seizures. It is also used short-term to treat insomnia, or as a sedative before surgery.
Phenobarbital (Vegaskine) may also be used for purposes not listed in this medication guide.
Phenobarbital (Vegaskine) indications
- Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of Phenobarbital (Vegaskine) is more than six hours. Included in the more common conditions in which the sedative Phenobarbital (Vegaskine) of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital (Vegaskine) is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital (Vegaskine) controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates.
- Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks.
- Long-term anticonvulsant, (Phenobarbital (Vegaskine), mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital (Vegaskine) sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting Phenobarbital (Vegaskine) sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression.
- Phenobarbital (Vegaskine) is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use.
How should I use Phenobarbital (Vegaskine)?
Use Phenobarbital (Vegaskine) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Phenobarbital (Vegaskine) is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Phenobarbital (Vegaskine) at home, a health care provider will teach you how to use it. Be sure you understand how to use Phenobarbital (Vegaskine). Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Do not use Phenobarbital (Vegaskine) if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- Do not suddenly stop using Phenobarbital (Vegaskine) or change the dose without checking with your doctor.
- Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
- If you miss a dose of Phenobarbital (Vegaskine), use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Phenobarbital (Vegaskine).
Uses of Phenobarbital (Vegaskine) in details
This medication is used alone or with other medications to control seizures. Controlling and reducing seizures lets you do more of your normal daily activities, reduces your risk of harm when you lose consciousness, and lessens your risk for a possibly life-threatening condition of frequent, repeated seizures. Phenobarbital (Vegaskine) belongs to a class of drugs known as barbiturate anticonvulsants/hypnotics. It works by controlling the abnormal electrical activity in the brain that occurs during a seizure. This medication is also used for a short time (usually no more than 2 weeks) to help calm you or help you sleep during periods of anxiety. It works by affecting certain parts of the brain to cause calming.
How to use Phenobarbital (Vegaskine)
Take this medication by mouth with or without food, usually once daily at bedtime for seizure control, or as directed by your doctor. Take with food or milk if stomach upset occurs. If you are using the liquid form of this medication, measure the dose carefully using a special measuring device/cup. Do not use a household spoon because you may not get the correct dose.
Dosage is based on your medical condition, Phenobarbital (Vegaskine) blood levels, and response to treatment. The dosage in children may also be based on weight.
Your doctor may direct you to start this medication at a low dose and gradually increase your dose to prevent side effects such as drowsiness and dizziness. Follow your doctor's instructions carefully. Do not take more or less of this drug than prescribed.
It may take several weeks to reach the best dose for you and completely control your seizures. This medication works best when the amount of drug in your body is kept at a constant level. Therefore, take it at the same time(s) each day.
Do not stop taking this medication (and other anticonvulsant medications) without consulting your doctor. Your seizures may worsen or cause a very severe seizure that is difficult to treat (status epilepticus) when this drug is suddenly stopped.
This medication may cause withdrawal reactions, especially if it has been used regularly for a long time or in high doses. In such cases, withdrawal symptoms (such as anxiety, hallucinations, twitching, trouble sleeping) may occur if you suddenly stop using this medication. Withdrawal from Phenobarbital (Vegaskine) can be severe and include seizures and (rarely) death. To prevent withdrawal reactions, your doctor may reduce your dose gradually. Consult your doctor or pharmacist for more details, and report any withdrawal reactions right away.
Along with its benefits, this medication may rarely cause abnormal drug-seeking behavior (addiction). This risk may be increased if you have abused alcohol or drugs in the past. Take this medication exactly as prescribed to lessen the risk of addiction.
When this medication is used for a long time for anxiety or to help you sleep, it may not work as well. Phenobarbital (Vegaskine) should only be used for a short time for anxiety or sleep. Talk with your doctor if this medication stops working well.
Tell your doctor if your anxiety or seizure control worsens (such as the number of seizures increases).
Phenobarbital (Vegaskine) description
A barbiturate that is metabolized to Phenobarbital (Vegaskine). It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over Phenobarbital (Vegaskine).
Phenobarbital (Vegaskine) dosage
Suggested doses of Phenobarbital (Vegaskine) for specific indications are as follows:
Oral Dosage (as recommended by the American Academy of Pediatrics):
Preoperative: 1 to 3 mg/kg.
Dosages of Phenobarbital (Vegaskine) must be individualized with full knowledge of their particular characteristics and recommended rate of administration. Factors of consideration are the patient's age, weight, and condition.
Parenteral routes should be used only when oral administration is impossible or impractical.
Anticonvulsant use: A therapeutic anticonvulsant level of Phenobarbital (Vegaskine) in serum is 10 to 25 µg/mL. To achieve the blood levels considered therapeutic in children, higher per-kilogram dosages are generally necessary for Phenobarbital (Vegaskine) and most other anticonvulsants. In children and infants, Phenobarbital (Vegaskine) at loading dose of 15 to 20 mg/kg produces blood levels of about 20 µg/mL shortly after administration.
In status epilepticus, it is imperative to achieve therapeutic blood levels of Phenobarbital (Vegaskine) as rapidly as possible. Because a barbiturate-induced depression may occur along with a postictal depression once the seizures are controlled, it is important, therefore, to use the minimal amount required, and to wait for the anticonvulsant effect to develop before administering a second dose.
Phenobarbital (Vegaskine) has been used in the treatment and prophylaxis of febrile seizures. However, it has not been established that prevention of febrile seizures influences the subsequent development of epilepsy.
Special patient population: Dosage should be reduced in the elderly or debilitated because these patients may be more sensitive to Phenobarbital (Vegaskine). Dosage should be reduced for patients with impaired renal function or hepatic disease.
15 mg - Each white round tablet imprinted Þ 026 contains 15 mg of Phenobarbital (Vegaskine). Tablets are supplied in bottles of 1000 (NDC 0228-2026-96).
30 mg - Each white, round, scored tablet imprinted Þ 028 contains 30 mg of Phenobarbital (Vegaskine). Tablets are supplied in bottles of 1000 (NDC 0228-2028-96).
100 mg - Each white, round, scored tablet imprinted Þ 030 contains 100 mg of Phenobarbital (Vegaskine). Tablets are supplied in bottles of 1000 (NDC 0228-2030-96).
Dispense in well-closed containers as defined in the USP. Store at controlled room temperature 15º- 30º C (59º- 86º F).
Red, clear elixir contains 20 mg of Phenobarbital (Vegaskine) per teaspoon (5 ml). Alcohol 13% by volume. Elixir is supplied in pints (NDC 0228-2024-16).
Preserve and dispense in tight, light- resistant containers as defined in the USP. Store at controlled room temperature 15º- 30ºC (59º- 86º F).
Phenobarbital (Vegaskine) interactions
Most reports of clinically significant drug interactions occurring with the barbiturates have involved Phenobarbital (Vegaskine).
1. Anticoagulants: Phenobarbital (Vegaskine) lowers the plasma levels of dicumarol (name previously used: bishydorxycoumarin) and causes a decrease in anticoagulant activity as measured by the prothrombin time. Phenobarbital (Vegaskine) can induce hepatic microsomal enzymes resulting in increased metabolism and decreased anticoagulant response of oral anticoagulants (e.g., warfarin, acenocournarol, dicumarol, and phenprocoumon). Patients stabilized on anticoagulant therapy may require dosage adjustments if Phenobarbital (Vegaskine) is added to or withdrawn from their dosage regimen.
2. Corticosteroids: Phenobarbital (Vegaskine) appears to enhance the metabolism of exogenous corticosteroids probably through the induction of hepatic microsomal enzymes. Patients stabilized on corticosteroid therapy may require dosage adjustments if Phenobarbital (Vegaskine) is added to or withdrawn from their dosage regimen.
3. Griseofulvin: Phenobarbital (Vegaskine) appears to interfere with the absorption of orally administered griseofulvin, thus decreasing its blood level. The effect of the resultant decreased blood levels of griseofulvin on therapeutic response has not been established. However, it would be preferable to avoid concomitant administration of these drugs.
4. Doxycycline: Phenobarbital (Vegaskine) has been shown to shorten the half- life of doxycycline for as long as 2 weeks after barbiturate therapy is discontinued. This mechanism is probably through the induction of hepatic microsomal enzymes that metabolize the antibiotic. If Phenobarbital (Vegaskine) and doxycycline are administered concurrently, the clinical response to doxycycline should be monitored closely.
5. Phenytoin, sodium valproate, valproic acid: The effect of Phenobarbital (Vegaskine) on the metabolism of phenytoin appears to be variable. Some investigators report an accelerating effect, while others report no effect. Because the effect of Phenobarbital (Vegaskine) on the metabolism of phenytoin is not predictable, phenytoin and Phenobarbital (Vegaskine) blood levels should be monitored more frequently if these drugs are given concurrently. Sodium valproate and valproic acid appear to decrease Phenobarbital (Vegaskine) metabolism; therefore, Phenobarbital (Vegaskine) blood levels should be monitored and appropriate dosage adjustments made as indicated.
6. Central nervous system depressants: The concomitant use of other central nervous system depressants including other sedatives or hypnotics, antihistamines, tranquilizers, or alcohol, may produce additive depressant effects.
7. Monoamine oxidase inhibitors (MAOIs): MAOIs prolong the effects of Phenobarbital (Vegaskine) probably because metabolism of the Phenobarbital (Vegaskine) is inhibited.
8. Estradiol, estrone, progesterone and other steroidal hormones: Pretreatment with or concurrent administration of Phenobarbital (Vegaskine) may decrease the effect of estradiol by increasing its metabolism. There have been reports of patients treated with antiepileptic drugs (e.g., Phenobarbital (Vegaskine)) who became pregnant while taking oral contraceptives. An alternate contraceptive method might be suggested to women taking Phenobarbital (Vegaskine).
Phenobarbital (Vegaskine) side effects
The following adverse reactions and their incidence were compiled from surveillance of thousands of hospitalized patients.
- Nervous system: Somnolence.
- Nervous system: Agitation, confusion, hyperkinesia, ataxia, CNS depression, nightmares, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormality.
- Respiratory system: Hypoventilation, apnea.
- Cardiovascular system: Bradycardia, hypotension, syncope.
- Digestive system: Nausea, vomiting, constipation.
- Other reported reactions: Headache, injection site reactions, hypersensitivity reactions (angioedema skin rashes, exfoliative dermatitis), fever, liver damage, megaloblastic anemia following chronic Phenobarbital (Vegaskine) use.
DRUG ABUSE AND DEPENDENCE
Symptoms of acute intoxication with Phenobarbital (Vegaskine) include unsteady gait, slurred speech, and sustained nystagmus. Mental signs of chronic intoxication include confusion, poor judgment, irritability, insomnia, and somatic complaints.
Symptoms of Phenobarbital (Vegaskine) dependence are similar to those of chronic alcoholism. If an individual appears to be intoxicated with alcohol to a degree that is radically disproportionate to the amount of alcohol in his or her blood, the use of barbiturates should be suspected. The lethal dose of a barbiturate is far less if alcohol is also ingested. The symptoms of Phenobarbital (Vegaskine) withdrawal can be severe and may cause death. Minor withdrawal symptoms may appear 8 to 12 hours after the last dose of Phenobarbital (Vegaskine). These symptoms usually appear in the following order: anxiety, muscle twitching, tremor of hands and fingers, progressive weakness, dizziness, distortion in visual perception, nausea, vomiting, insomnia, and orthostatic hypotension. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of this drug. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Individuals susceptible to Phenobarbital (Vegaskine) abuse and dependence include alcoholics and opiate abusers, as well as other sedative- hypnotic and amphetamine abusers.
Drug dependence on Phenobarbital (Vegaskine) arises from repeated administration of the barbiturate or an agent with barbiturate- like effect on a continuous basis, generally in amounts exceeding therapeutic dose levels. The characteristics of drug dependence on Phenobarbital (Vegaskine) include: (a) a strong desire or need to continue taking the drug, (b) a tendency to increase the dose, (c) a psychic dependence on the effects of the drug related to subjective and individual appreciation of those effects, and (d) a physical dependence on the effects of the drug requiring its presence for maintenance of homeostasis and resulting in a definite, characteristic, and self-limited abstinence syndrome when the drug is withdrawn.
Treatment of Phenobarbital (Vegaskine) dependence consists of cautious and gradual withdrawal of the drug. One method involves substituting a 30 mg dose of Phenobarbital (Vegaskine) for each 100 to 200 mg dose that the patient has been taking. The total daily amount of Phenobarbital (Vegaskine) is then administered in 3 to 4 divided doses, not to exceed 600 mg daily. Should signs of withdrawal occur on the first day of treatment, a loading dose of 100 to 200 mg of Phenobarbital (Vegaskine) may be administered IM in addition to the oral dose. After stabilization on Phenobarbital (Vegaskine), the total daily dose is decreased by 30 mg a day as long as withdrawal is proceeding smoothly. A modification of this regimen involves initiating treatment at the patient's regular dosage level and decreasing the daily dosage by 10 percent if tolerated by the patient.
Infants physically dependent on Phenobarbital (Vegaskine) may be given a lower dose of Phenobarbital (Vegaskine) at 3 to 10 mg/kg/day. After withdrawal symptoms (hyperactivity, disturbed sleep, tremors, hyperreflexia) are relieved, the dosage of Phenobarbital (Vegaskine) should be gradually decreased and completely withdrawn over a 2-week period.
Phenobarbital (Vegaskine) contraindications
Do not use Phenobarbital (Vegaskine) if you are pregnant. It could harm the unborn baby. Phenobarbital (Vegaskine) may also cause addiction or withdrawal symptoms in a newborn if the mother takes the medication during pregnancy.
Phenobarbital (Vegaskine) can make birth control pills less effective. Ask your doctor about using a non-hormone method of birth control (such as a condom, diaphragm, spermicide) to prevent pregnancy while taking Phenobarbital (Vegaskine).
Phenobarbital (Vegaskine) may cause a severe allergic reaction. Stop taking Phenobarbital (Vegaskine) and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Do not stop using Phenobarbital (Vegaskine) without first talking to your doctor, even if you feel better. You may have increased seizures if you stop using Phenobarbital (Vegaskine) suddenly. You will need to use less and less before you stop the medication completely.
Some people using this medicine have engaged in activity such as driving, eating, or making phone calls and later having no memory of the activity. If this happens to you, stop taking Phenobarbital (Vegaskine) and talk with your doctor about another treatment for your sleep disorder.
Phenobarbital (Vegaskine) may be habit-forming and should be used only by the person it was prescribed for. Keep the medication in a secure place where others cannot get to it.
What is Phenylpropanolamine (Vegaskine)?
Phenylpropanolamine (Vegaskine) is a decongestant. It works by constricting (shrinking) blood vessels (veins and arteries) in your body. Constriction of blood vessels in your sinuses, nose, and chest allows drainage of those areas, which decreases congestion.
Phenylpropanolamine (Vegaskine) is used to treat the congestion associated with allergies, hay fever, sinus irritation, and the common cold. Phenylpropanolamine (Vegaskine) also causes a decrease in appetite and is used in some over-the-counter diet aids.
Phenylpropanolamine (Vegaskine) has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain Phenylpropanolamine (Vegaskine).
Phenylpropanolamine (Vegaskine) may also be used for purposes other than those listed in this medication guide.
Phenylpropanolamine (Vegaskine) indications
Adult: Per cap contains a combination w/ Phenylpropanolamine (Vegaskine) HCl 18 mg: ≥13 yr 2 cap 4 hrly. Max: 8 cap/day. Per tab contains a combination w/ Phenylpropanolamine (Vegaskine) HCl 25 mg: ≥13 yr 1 tab 4 hrly. Max: 4 tab/day.
Child: Per cap contains a combination w/ Phenylpropanolamine (Vegaskine) HCl 18 mg: 6-12 yr 1 cap 4 hrly. Max: 4 cap/day. As oral liquid containing Phenylpropanolamine (Vegaskine) 2.5 mg/5 mL: 6 mth-2 yr 2.5 mL tid, 3-5 yr 5 mL 3-4 times daily, 6-12 yr 5-10 mL 3-4 times daily.
Uses of Phenylpropanolamine (Vegaskine) in details
Phenylpropanolamine (Vegaskine) is used to relieve blocked nose or sinuses caused by common cold and seasonal nasal allergies (hay fever). It is also used to decrease appetite for weight control.
Phenylpropanolamine (Vegaskine) description
Phenylpropanolamine (Vegaskine) has been withdrawn in Canada and the United States. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug.
Phenylpropanolamine (Vegaskine) dosage
Phenylpropanolamine (Vegaskine) Dosage
Applies to the following strengths: 75 mg; 25 mg; 37.5 mg; 50 mg; 180 mg-75 mg
Usual Adult Dose for:
- Nasal Congestion
- Weight Loss
Usual Pediatric Dose for:
- Nasal Congestion
Additional dosage information:
- Renal Dose Adjustments
- Other Comments
Usual Adult Dose for Nasal Congestion
25 mg orally every 4 hours.
75 mg orally extended release every 12 hours.
Not to exceed 150 mg/day.
Usual Adult Dose for Weight Loss
25 mg orally 3 times a day, one-half hour before meals.
75 mg orally extended release once a day in the morning.
The use of Phenylpropanolamine (Vegaskine) for weight loss should be limited to 12 weeks.
Usual Pediatric Dose for Nasal Congestion
2 to 6 years:
6.25 mg orally every 4 hours. Maximum daily dose is 37.5 mg.
6 to 12 years:
12.5 mg orally every 4 hours. Maximum daily dose is 75 mg.
> 12 years:
25 mg orally every 4 hours.
75 mg orally extended release every 12 hours.
Not to exceed 150 mg/day.
Renal Dose Adjustments
Because Phenylpropanolamine (Vegaskine) is eliminated primarily by the kidneys, one-half of the normally recommended dosage should be given. Patients with renal dysfunction should be monitored for signs and symptoms of toxicity when using Phenylpropanolamine (Vegaskine).
In November 2000, the Food and Drug Administration (FDA), in response to reports of increased risk of hemorrhagic stroke, requested that all drug companies discontinue marketing products containing Phenylpropanolamine (Vegaskine).
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Phenylpropanolamine (Vegaskine)
- Phenylpropanolamine (Vegaskine) Side Effects
- During Pregnancy
- Drug Interactions
- Support Group
- 2 Reviews
- Drug class: decongestants
Related treatment guides
- Weight Loss
- Cold Symptoms
- Nasal Congestion
Phenylpropanolamine (Vegaskine) interactions
It is important to tell your doctor or pharmacist what medicines you are already taking, including those bought without a prescription and herbal medicines, before you take this medicine. Similarly, check with your doctor or pharmacist before taking any new medicines while taking this one, to ensure that the combination is safe.
You should not take other medicines that contain Phenylpropanolamine (Vegaskine) in combination with this medicine, as this can easily result in exceeding the maximum recommended daily dose of Phenylpropanolamine (Vegaskine). Many cold and flu remedies and over-the-counter painkillers contain Phenylpropanolamine (Vegaskine), so be sure to check the ingredients of any other medicines before taking them with this one. Migraleve yellow can be taken four hours after taking Migraleve pink if you still have a migraine, but make sure you do not exceed the maximum dose recommended in the information leaflet.
This medicine should be used with caution in people taking a monoamine oxidase inhibitor (MAOI), for example the antidepressants phenelzine, tranylcypromine or isocarboxacid. Ask your doctor or pharmacist for advice before taking this medicine if you have taken an MAOI in the last 14 days.
Cholestyramine reduces the absorption of Phenylpropanolamine (Vegaskine) from the gut. It should not be taken within an hour of taking Phenylpropanolamine (Vegaskine) or the effect of the Phenylpropanolamine (Vegaskine) will be reduced.
Metoclopramide and domperidone may increase the absorption of Phenylpropanolamine (Vegaskine) from the gut.
Long-term or regular use of Phenylpropanolamine (Vegaskine) may increase the anti-blood-clotting effect of warfarin and other anticoagulant medicines, leading to an increased risk of bleeding. This effect does not occur with occasional painkilling doses. If you are taking an anticoagulant medicine and you are also taking co-codamol regularly, your blood clotting time (INR) should be regularly monitored.
In the unlikely event that this medicine makes you feel drowsy, this may be enhanced by other medicines that can cause drowsiness, such as the following:
antipsychotics, eg haloperidol
barbiturates, eg Phenylpropanolamine (Vegaskine), amobarbital
benzodiazepines, eg diazepam, temazepam
other opioids, eg morphine, dihydrocodeine
sedating antihistamines, eg Phenylpropanolamine (Vegaskine), hydroxyzine
sleeping tablets, eg zopiclone
tricyclic antidepressants, eg amitriptyline.
Phenylpropanolamine (Vegaskine) side effects
Medicines and their possible side effects can affect individual people in different ways. The following are some of the side effects that are known to be associated with this medicine. Just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect.
Codeine can cause drowsiness, although at the dose contained in this medicine this is very unlikely. However, if you do find this medicine makes you feel sleepy or dizzy you should not drive or operate machinery and avoid alcoholic drink.
The side effects listed above may not include all of the side effects reported by the medicines’s manufacturer. For more information about any other possible risks associated with this medicine, please read the information provided with the medicine or consult your doctor or pharmacist.
Phenylpropanolamine (Vegaskine) contraindications
Decreased kidney function.
Decreased liver function.
Children under 10 years of age, unless on the advice of a doctor.
This medicine should not be used if you are allergic to any of its ingredients. Please inform your doctor or pharmacist if you have previously experienced such an allergy.
If you feel you have experienced an allergic reaction, stop using this medicine and inform your doctor or pharmacist immediately.
Active ingredient matches for Vegaskine:
List of Vegaskine substitutes (brand and generic names)
|Sort by popularity|
|Unit description / dosage (Manufacturer)||Price, USD|
- PubChem. "phenobarbital". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "phenobarbital". http://www.drugbank.ca/drugs/DB01174 (accessed September 17, 2018).
- DTP/NCI. "phenobarbital: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Vegaskine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Vegaskine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology